Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „Jakavi“
Suchtreffer
Begriffe & Kennungen
Jakavi · 4.8 · Chronic GvHD The most frequently reported adverse drug reactions in REACH3 (adult and adolescent patients) wer
Eintrag öffnenJakavi · 4.8 · Description of selected adverse drug reactions
Eintrag öffnenJakavi · 4.8 · Description of selected adverse drug reactions
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 an
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 an
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 19.4% of patients.
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients in REACH2 an
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 30.0% of patients.
Eintrag öffnenJakavi · 4.8 · During long-term follow-up of phase 3 studies in PV, frequently reported infections were urinary tract infecti
Eintrag öffnenJakavi · 4.8 · During the long-term follow-up of phase 3 clinical studies in MF, the cumulative frequency of bleeding events
Eintrag öffnenJakavi · 4.8 · During the long-term follow-up of phase 3 studies in PV, the cumulative frequency of bleeding events increased
Eintrag öffnenJakavi · 4.8 · Elderly A total of 29 patients in study REACH2 and 25 patients in REACH3 aged >65 years and treated with ruxol
Eintrag öffnenJakavi · 4.8 · Elevated lipase In the randomised period of the RESPONSE study, the worsening of lipase values was higher in t
Eintrag öffnenJakavi · 4.8 · Haematological adverse drug reactions (any Common Terminology Criteria for Adverse Events [CTCAE] grade) inclu
Eintrag öffnenJakavi · 4.8 · Haematological adverse reactions (any CTCAE grade) included anaemia (61.8%), thrombocytopenia (25.0%) and neut
Eintrag öffnenJakavi · 4.8 · Haematological laboratory abnormalities identified as adverse drug reactions in REACH2 (adult and adolescent p
Eintrag öffnenJakavi · 4.8 · Haematological laboratory abnormalities identified as adverse drug reactions in REACH2 (adult and adolescent p
Eintrag öffnenJakavi · 4.8 · Haematological laboratory abnormalities identified as adverse drug reactions in REACH3 (adult and adolescent p
Eintrag öffnenJakavi · 4.8 · Haematological laboratory abnormalities identified as adverse drug reactions in REACH3 (adult and adolescent p
Eintrag öffnenJakavi · 4.8 · In patients receiving ruxolitinib mean decreases in haemoglobin reached a nadir of approximately 10 g/litre be
Eintrag öffnen